DaVita HealthCare (DVA) Rises As Market Takes a Dip: Key Facts

DaVita HealthCare (DVA) ended the recent trading session at $151.37, demonstrating a +0.39% swing from the preceding day's closing price. The stock's change was more than the S&P 500's daily loss of 1.12%. Elsewhere, the Dow lost 0.31%, while the tech-heavy Nasdaq lost 2.04%.The the stock of kidney dialysis provider has risen by 5.46% in the past month, leading the Medical sector's loss of 2.99% and the S&P 500's loss of 2.91%.The investment community will be closely monitoring the performance of DaVita HealthCare in its forthcoming earnings report. The company is predicted to post an EPS of $1.75, indicating a 26.47% decline compared to the equivalent quarter last year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $3.23 billion, up 5.27% from the year-ago period.Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $10.76 per share and revenue of $13.47 billion, indicating changes of +11.16% and +5.08%, respectively, compared to the previous year.Investors should also note any recent changes to analyst estimates for DaVita HealthCare. These revisions help to show the ever-changing nature of near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the company's business and profitability.Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, there's been no change in the Zacks Consensus EPS estimate. Right now, DaVita HealthCare possesses a Zacks Rank of #3 (Hold).Investors should also note DaVita HealthCare's current valuation metrics, including its Forward P/E ratio of 14.01. This valuation marks a discount compared to its industry's average Forward P/E of 20.9.Investors should also note that DVA has a PEG ratio of 1.11 right now. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. DVA's industry had an average PEG ratio of 2.08 as of yesterday's close.The Medical - Outpatient and Home Healthcare industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 56, which puts it in the top 23% of all 250+ industries.The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.Zacks Names #1 Semiconductor StockIt's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom.With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028.See This Stock Now for Free >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DaVita Inc. (DVA): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks